lobbying_activities: 3146520
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3146520 | 63947e55-143d-4659-a0ee-68c1da8b12ed | Q1 | EMERGENT BIOSOLUTIONS INC. | 304931 | EMERGENT BIOSOLUTIONS INC | 2024 | first_quarter | DIS | Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24 and FY25. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. State opioid response (SOR) Grant funding for FY24 and FY25. Substance Abuse and Mental Health Block Grant (SABG) funding for FY24 and FY25. NDAA for Fiscal Year 2024 and Fiscal Year 2025 - provisions related to biological and chemical defense and access to naloxone. FAA reauthorization - increasing access to naloxone. HANDS Act - H.R.5506. SAVE Act of 2023 - H.R.6161. Overdose Reversal Medication (ORM) Act - H.R.6243. Workplace Overdose Reversal Kits (WORK) to Save Lives Act - H.R.5420, S.2948. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 760000 | 0 | 0 | 2024-04-16T13:30:20-04:00 |